Capsaicin Patch 8% (Qutenza)
capsaicin topical system
Capsaicin Patch Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Neuropathic pain associated with post-herpetic neuralgia (PHN) | Adults | Single 60-min topical application; monotherapy or adjunct | FDA Approved (2009) |
| Neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet | Adults | Single 30-min topical application to the feet | FDA Approved (2020) |
Qutenza is a high-concentration capsaicin (8%) topical system that achieves pain relief through defunctionalisation of TRPV1-expressing nociceptive nerve endings. It is the only prescription-strength capsaicin patch available. Approval for PHN was based on two pivotal 12-week, double-blind, dose-controlled trials showing pain reductions of 29.6–32% from baseline with Qutenza versus 19.9–24.4% with a low-dose control (P ≤ 0.01). Pain relief begins within the first week and can persist for up to 3 months, with re-treatment every 3 months as needed. The capsaicin patch offers a distinct advantage as a non-systemic, non-opioid option with no drug-drug interactions and no dose adjustment in renal or hepatic impairment.
HIV-associated neuropathy — Phase 3 trials demonstrated efficacy; contributed to the evidence base for capsaicin patch in peripheral neuropathies. Not a current FDA-approved indication. Evidence quality: Moderate.
Other focal neuropathic pain syndromes — Case series and small studies suggest potential benefit in surgical scar pain, post-amputation stump pain, and complex regional pain syndrome. Evidence quality: Low.
Capsaicin Patch Dosing
Dosing — By Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Post-herpetic neuralgia — adults | Up to 4 patches for 60 min | Repeat every 3 months as needed | 4 patches per application; not more frequently than q3 months | Pre-treat area with topical anaesthetic (optional per 2024 PI) Patches may be cut to fit the treatment area; apply only to intact, dry skin |
| Diabetic peripheral neuropathy — feet | Up to 4 patches for 30 min on feet | Repeat every 3 months as needed | 4 patches per application; not more frequently than q3 months | Examine feet for skin lesions before each application Patches can be wrapped around dorsal, lateral, and plantar surfaces of each foot |
| Elderly patients (≥65 years) | Same as adult dosing | No dose adjustment required | 4 patches; q3 months | 75% of PHN trial patients were ≥65 years; similar safety and efficacy No age-related differences in safety or effectiveness observed |
Even with pre-treatment using a topical anaesthetic, patients commonly experience substantial burning pain during and immediately after the 60-minute application. Pain scores typically return to baseline by the end of the treatment day. Have ice packs and oral analgesics (including opioids if needed) readily available during the procedure. Transient blood pressure elevations averaging <10 mmHg may occur during application, related to procedural pain rather than a direct pharmacological effect. Monitor blood pressure periodically during and for approximately 2 hours after treatment.
Pharmacology
Mechanism of Action
Capsaicin is a potent and selective agonist of the transient receptor potential vanilloid 1 (TRPV1) receptor, an ion channel expressed predominantly on nociceptive C-fibres and some A-delta fibres in the skin. When the high-concentration 8% patch is applied, capsaicin initially activates TRPV1 channels causing an intense calcium influx, which produces the characteristic burning pain during application. Sustained exposure then leads to defunctionalisation of the nociceptive nerve endings through multiple mechanisms: pharmacological desensitisation of TRPV1, overwhelming of intracellular calcium buffering capacity with cytoskeleton breakdown, and reversible retraction of epidermal nerve fibre terminals. Crucially, because TRPV1 is selectively expressed on nociceptive neurons, non-nociceptive sensory fibres (A-beta fibres mediating touch and proprioception) remain functionally intact. The resulting reduction in nociceptive input provides pain relief lasting up to 3 months, after which nerve fibre regeneration can occur and re-treatment may be warranted.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Negligible systemic absorption; transient plasma levels <5 ng/mL detected in ~1/3 of PHN patients; highest Cmax detected: 4.6 ng/mL (immediately after 60-min removal) (FDA PI) | The drug acts locally at the application site; systemic exposure is too low to produce systemic effects or drug-drug interactions |
| Distribution | Not characterised in humans due to negligible systemic absorption; capsaicin crosses placental barrier in animals; excreted in rat milk (FDA PI) | Maternal systemic exposure following topical application is not expected to result in fetal exposure |
| Metabolism | Unknown whether metabolised in skin; no detectable metabolites in plasma samples; in vitro: does not inhibit or induce CYP450 enzymes at concentrations far exceeding those measured in blood (FDA PI) | No hepatic dose adjustment needed; no pharmacokinetic drug interactions expected |
| Elimination | Plasma levels below limit of quantitation within 3–6 h of patch removal; no accumulation data needed given single-dose q3-month regimen (FDA PI) | Rapid clearance from any transiently absorbed capsaicin; no concern for drug accumulation between treatments |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Application site erythema | 63% (PHN); vs 54% control (FDA PI Table 1) | Most common reaction; generally mild and transient; resolves spontaneously; partially attributable to capsaicin’s vasodilatory action on dermal vessels |
| Application site pain / burning | 42% vs 21% control (PHN); 14% burning + 10% pain vs 3%/2% control (DPN) (FDA PI Tables 1–2) | Expected pharmacological effect; begins during application and usually resolves by end of treatment day; pre-treatment with topical anaesthetic and ice packs recommended |
| Pain in extremity (DPN) | 11% vs 6% control (FDA PI Table 2) | Reported specifically in the DPN foot indication; likely reflects procedural pain and underlying neuropathy interaction |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Application site pruritus | 6% vs 4% (PHN) | Usually self-limited; part of the transient inflammatory response |
| Application site papules | 6% vs 3% (PHN) | Mild dermal reaction; resolves without intervention |
| Nausea | 5% vs 2% (PHN) | May be related to procedural pain and stress response; typically resolves after treatment day |
| Application site edema | 4% vs 1% (PHN) | Localised; reflects capsaicin-induced neurogenic inflammation |
| Nasopharyngitis / URI | 4% vs 2% (PHN); 4% vs <1% (DPN) | Causality uncertain; may reflect coincidental infection during 12-week follow-up |
| Vomiting | 3% vs 1% (PHN) | Related to procedural pain; manage with antiemetics if needed |
| Sinusitis / bronchitis | 2–3% vs 1% (PHN) | Could reflect airborne capsaicin exposure in inadequately ventilated rooms |
| Hypertension | 2% vs 1% (PHN); 2% vs <1% (DPN) | Transient; averages <10 mmHg; pain-related rather than pharmacological; lasts ~2 h after removal |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Severe application site burns (2nd and 3rd degree) | Rare (post-marketing reports) | During or after application; reported with unapproved indications, excessive frequency, or prior skin trauma | Immediate removal; cleansing gel; wound care; hospitalisation and skin grafting may be required for full-thickness burns |
| Transient blood pressure elevation (>10 mmHg) | Uncommon (subset of the 2% hypertension rate) | During application; lasting ~2 h after removal | Monitor BP during and after procedure; patients with unstable hypertension or recent CV/cerebrovascular events are at increased risk; consider risk-benefit before treatment |
| Accidental capsaicin exposure (eyes, mucous membranes, respiratory tract) | Rare (post-marketing) | During handling/application or from aerosolisation during rapid removal | Flush eyes with cool water; remove from area; supportive respiratory care if shortness of breath; strict adherence to nitrile glove and ventilation requirements |
| Sensory loss / deterioration | Generally minor and temporary (reversible ENF density reduction) | Days to weeks post-application; reflects intended pharmacological mechanism | Assess sensory function before each re-treatment; if sensory deterioration worsens or does not resolve, reconsider continued use |
Application site pain (42% in PHN trials) is the most clinically significant adverse effect and is a direct consequence of TRPV1 activation. This is an expected pharmacological effect, not an adverse reaction in the traditional sense. Pre-treatment with a topical anaesthetic is optional per the current label. Have ice packs, oral NSAIDs, and short-acting opioids available for the procedure. Pain typically resolves within hours of patch removal and does not predict treatment failure — in fact, the intensity of application-site burning does not correlate with the subsequent degree of pain relief.
Drug Interactions
No clinical drug interaction studies have been performed. Because capsaicin is negligibly absorbed systemically and does not inhibit or induce hepatic CYP450 enzymes at concentrations far exceeding those measured in clinical use, interactions with systemic medications are considered unlikely. This is a major clinical advantage of the capsaicin patch over systemic neuropathic pain therapies such as gabapentinoids, TCAs, and SNRIs, which carry extensive interaction profiles.
Monitoring
-
Blood Pressure
During and ~2 h after application
Routine Transient increases averaging <10 mmHg are common and pain-related. Monitor periodically during the application procedure and for approximately 2 hours after patch removal. Consider risk-benefit in patients with unstable hypertension or recent cardiovascular/cerebrovascular events. -
Application Site
During, immediately after, and at each re-treatment visit
Routine Inspect for erythema, blistering, burns, or skin breakdown. In DPN patients, perform a careful foot examination before each application to detect skin lesions related to underlying neuropathy or vascular insufficiency. Do not apply to broken or non-intact skin. -
Sensory Function
Before each re-treatment
Routine Assess for signs of sensory deterioration or loss prior to each Qutenza application. ENF density reduction is expected and generally reversible. If sensory loss worsens or does not resolve between treatments, reconsider continued use. -
Pain Response
At 1–2 weeks, then q3 months
Routine Pain relief typically begins within Week 1 and persists through 12 weeks. Assess using NPRS or VAS at follow-up. Re-treatment every 3 months if pain recurs; do not re-treat more frequently than every 3 months. -
HCP Exposure
Each application
Routine Healthcare professionals must wear nitrile (not latex) gloves and work in a well-ventilated area. Remove Qutenza slowly by rolling inward to avoid aerosolisation. Monitor staff for coughing, sneezing, eye irritation, or skin exposure. Face mask and protective glasses are advisable.
Contraindications & Cautions
Absolute Contraindications
- None listed in the current FDA PI (revised July 2024). The contraindications section states: “None.”
Relative Contraindications (Specialist Input Recommended)
- Broken, non-intact, or inflamed skin at the treatment site — the PI states QUTENZA should only be used on dry, intact (unbroken) skin; application to compromised skin may increase absorption and risk of burns
- Unstable or poorly controlled hypertension — transient BP increases occur during treatment; patients with recent cardiovascular or cerebrovascular events may be at increased risk of adverse cardiovascular effects
- Progressive sensory deterioration at the treatment site — if pre-existing sensory deficits worsen, treatment should be reconsidered
Use with Caution
- Application to the face, eyes, mouth, nose, or scalp — strictly prohibited to avoid risk of exposure to mucous membranes
- DPN patients with foot ulcers or vascular insufficiency — perform careful foot examination before each application
- Self-administration — Qutenza must NOT be dispensed to patients; it is for physician/HCP administration only
Post-marketing reports describe full-thickness (third-degree) and deep partial-thickness (second-degree) burns following Qutenza administration. Cases of third-degree burns requiring hospitalisation and skin grafting have been reported in patients treated for unapproved indications, with excessive frequency of dosing, or at application sites where there had been prior skin trauma. Ensure strict adherence to dosage and administration recommendations: use only on dry, intact skin, apply for the correct duration (60 min PHN / 30 min DPN), and do not re-treat more frequently than every 3 months.
Patient Counselling
Purpose of Therapy
The Qutenza patch is a high-strength capsaicin treatment applied by a healthcare professional in a clinical setting. It works by temporarily reducing the activity of pain-sensing nerve endings in the skin. A single application can provide pain relief for up to 3 months, after which the treatment can be repeated. It is used specifically for nerve pain from shingles (post-herpetic neuralgia) or diabetic nerve damage in the feet.
What to Expect During Treatment
The patch is applied for 60 minutes (PHN) or 30 minutes (DPN of feet). During the application, you will likely experience burning, stinging, or intense warmth at the treatment site. This is a normal part of how the medication works. Your healthcare team will provide pain relief measures such as ice packs and pain medications. This burning usually fades within hours after the patch is removed.
Sources
- Qutenza (capsaicin) topical system. Full Prescribing Information. Averitas Pharma, Inc. NDA 022395. Revised July 2024. FDA Label Primary source for all dosing (60 min PHN / 30 min DPN), adverse reaction incidence tables (Tables 1 and 2), PK data, warnings, and contraindications.
- Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 2008;7(12):1106-1112. doi:10.1016/S1474-4422(08)70228-X Pivotal Phase 3 RCT establishing Qutenza efficacy in PHN with 32% pain reduction vs 24.4% control (P = 0.011).
- Irving GA, Backonja MM, Dunteman E, et al. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med. 2011;12(1):99-109. doi:10.1111/j.1526-4637.2010.01004.x Second pivotal PHN trial (n=418) demonstrating 29.6% pain reduction with Qutenza vs 19.9% control (P = 0.003).
- Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study. J Pain. 2017;18(1):42-53. doi:10.1016/j.jpain.2016.09.008 Key trial supporting the DPN indication; demonstrated efficacy of 30-minute foot application.
- Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237-251. doi:10.1016/j.pain.2007.08.033 IASP NeuPSIG guidelines recommending topical capsaicin (high concentration) as a treatment option for localised neuropathic pain.
- Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-173. doi:10.1016/S1474-4422(14)70251-0 NeuPSIG updated systematic review recommending capsaicin 8% patches as second-line treatment for peripheral neuropathic pain (NNT 10.6).
- Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107(4):490-502. doi:10.1093/bja/aer260 Comprehensive review of TRPV1 defunctionalisation mechanisms, ENF density changes, and the pharmacological basis for capsaicin’s prolonged analgesic effect.
- Kennedy WR, Vanhove GF, Lu SP, et al. A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J Pain. 2010;11(6):579-587. doi:10.1016/j.jpain.2009.09.019 Demonstrated that ENF density reduction and minor sensory changes following Qutenza were fully reversible, confirming the safety of repeated application.
- Jones VM, Moore KA, Peterson DM. Capsaicin 8% topical patch (Qutenza) — a review of the evidence. J Pain Palliat Care Pharmacother. 2011;25(1):32-41. doi:10.3109/15360288.2010.547561 Comprehensive review reporting erythema (63%) and pain (42%) as most common ADRs; summarised pivotal trial efficacy data (29.6–32% pain reduction vs 19.9–24.4% control).
- Babbar S, Marier JF, Mouksassi MS, et al. Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain. Ther Drug Monit. 2009;31(4):502-510. doi:10.1097/FTD.0b013e3181a8b200 PK study confirming transient systemic exposure (<5 ng/mL), Cmax 4.6 ng/mL, and undetectable levels within 3–6 hours of removal.
- Cobzaru A, Grigore C, Bhatt A. High-concentration capsaicin patch (Qutenza) — a new step in treatment of neuropathic pain. Maedica (Bucur). 2012;7(2):141-145. PMC3484805 Review of TRPV1 receptor pharmacology, defunctionalisation mechanisms, and the rationale for single high-dose topical application in neuropathic pain.